BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12415797)

  • 1. [Familiarity and heredity of tumors in function of an early surgical therapeutic approach].
    Ricevuto E; Di Rocco ZC; Cianci G; Bisegna R; Casilli F; De Galitiis F; Cannita K; Calista F; Porzio G; Bafile A; Vicentini R; Resta V; De Rubeis G; Martinotti S; Ficorella C; Marchetti P
    Suppl Tumori; 2002; 1(3):S89-91. PubMed ID: 12415797
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
    Domchek SM; Rebbeck TR
    LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic surgery recommended for BRCA1 carriers.
    Cancer Discov; 2014 May; 4(5):OF1. PubMed ID: 24795013
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetics: predisposition and management.
    Legare RD
    Clin Obstet Gynecol; 2011 Mar; 54(1):180-90. PubMed ID: 21278518
    [No Abstract]   [Full Text] [Related]  

  • 5. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
    Agnantis NJ; Paraskevaidis E; Roukos D
    Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
    [No Abstract]   [Full Text] [Related]  

  • 6. BRCA1 and BRCA2 variants of uncertain significance. Part two: medical management.
    Miller-Samuel S; Rosenberg A; Berger A; Gomella L; Loren D; Morris GJ
    Semin Oncol; 2011 Oct; 38(5):605-11. PubMed ID: 21943665
    [No Abstract]   [Full Text] [Related]  

  • 7. Pretest genetic counseling informs patients with BRCA mutation.
    Printz C
    Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from genetic testing.
    Esserman L; Kaklamani V
    JAMA; 2010 Sep; 304(9):1011-2. PubMed ID: 20810382
    [No Abstract]   [Full Text] [Related]  

  • 10. Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate.
    Kauff N; Robson M
    Nat Rev Clin Oncol; 2015 Sep; 12(9):505-6. PubMed ID: 26196251
    [No Abstract]   [Full Text] [Related]  

  • 11. Familial breast and ovarian cancers.
    Arai M; Utsunomiya J; Miki Y
    Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choices--and uncertainties--for women with BRCA mutations.
    Couzin J
    Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
    [No Abstract]   [Full Text] [Related]  

  • 14. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inherited breast and ovarian cancers].
    Gerdes AM; Ejlertsen B
    Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
    Biglia N; Mariani L; Ponzone R; Sismondi P
    Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical counseling and care of women with genetic predisposition to breast and ovarian carcinoma].
    Schmutzler RK; Kempe A; Kiechle M; Beckmann MW
    Dtsch Med Wochenschr; 1999 May; 124(18):563-6. PubMed ID: 10356583
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA testing: ethics lessons for the new genetics.
    Sherwin S
    Clin Invest Med; 2004 Feb; 27(1):19-22. PubMed ID: 15061582
    [No Abstract]   [Full Text] [Related]  

  • 20. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
    Leegte B; van der Hout AH; Deffenbaugh AM; Bakker MK; Mulder IM; ten Berge A; Leenders EP; Wesseling J; de Hullu J; Hoogerbrugge N; Ligtenberg MJ; Ardern-Jones A; Bancroft E; Salmon A; Barwell J; Eeles R; Oosterwijk JC
    J Med Genet; 2005 Mar; 42(3):e20. PubMed ID: 15744030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.